Search

Displaying results 1461 - 1470 of 3735 in total
  1. Drug

    Zanamivir

    go.drugbank.com/drugs/DB00558
    ApprovedInvestigational

    A guanido-neuraminic acid that is used to inhibit neuraminidase.

  2. Drug

    Maftivimab

    go.drugbank.com/drugs/DB15899
    ApprovedInvestigational

    [A221825, A221830] A recent large-scale study elucidated that both neutralizing and Fc-mediated functions of antibodies were important for therapeutic benefit in animal models of EBOV infection.

  3. Drug

    Dabigatran etexilate

    go.drugbank.com/drugs/DB06695
    ApprovedInvestigational

    Dabigatran etexilate is an oral prodrug that is hydrolyzed to the competitive and reversible direct thrombin inhibitor dabigatran. Dabigatran etexilate may be used to decrease the risk of venous thromboembolic events in patients in whom ...

    Categories: P-glycoprotein substrates
  4. Drug

    PF-232798

    go.drugbank.com/drugs/DB14813
    Investigational

    PF-232798 is under investigation in clinical trial NCT01140425 (Study To Evaluate The Effect Of A Multiple Oral Dose Of PF-00232798 On QT Intervals In Healthy Subjects).

    Synonyms: PF-00232798Categories: CCR5 Receptor Antagonists
  5. Drug

    Eribulin

    go.drugbank.com/drugs/DB08871
    ApprovedInvestigational

    Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated ...

  6. Drug

    Frangula purshiana bark

    go.drugbank.com/drugs/DB15478
    Approved

    Mixtures: Vita-lax
  7. Drug

    Cefditoren

    go.drugbank.com/drugs/DB01066
    Approved

    Cefditoren is an oral third-generation cephalosporin. It is commonly marketed under the trade name Spectracef by Cornerstone BioPharma.

  8. Drug

    SF1126

    go.drugbank.com/drugs/DB05210
    Investigational

    SF1126 is an integrin-targeted PI3 kinase inhibitor.

  9. Drug

    PF-04995274

    go.drugbank.com/drugs/DB12675
    Investigational

    Pf 04995274 is under investigation in clinical trial NCT01193062 (Study In Healthy Subjects To Evaluate The Changes In The Protein sAPP-Alpha In Cerebrospinal Fluid Following A Single Oral Dose Of PF-04995274

  10. Drug

    Bezlotoxumab

    go.drugbank.com/drugs/DB13140
    Approved

    Bezlotoxumab is a fully humanized ImmunoglobulinG1 (IgG1) kappa monoclonal antibody that binds to Clostridium difficile toxin B and neutralizes its effects. First approved by the FDA on October 21, 2016, bezlotoxumab is used to reduce th...